Copyright
©The Author(s) 2020.
World J Transplant. Nov 28, 2020; 10(11): 297-306
Published online Nov 28, 2020. doi: 10.5500/wjt.v10.i11.297
Published online Nov 28, 2020. doi: 10.5500/wjt.v10.i11.297
Figure 1 Metastatic site of hepatocellular recurrence after liver transplantation in a patient who received lenvatinib.
Figure 2 First- and second-line therapies for advanced hepatocellular carcinoma that may be applicable in the post-liver transplantation setting.
- Citation: Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306
- URL: https://www.wjgnet.com/2220-3230/full/v10/i11/297.htm
- DOI: https://dx.doi.org/10.5500/wjt.v10.i11.297